CStone Pharmaceuticals

SEHK:2616 Stock Report

Market Cap: HK$3.0b

CStone Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

CStone Pharmaceuticals has been growing earnings at an average annual rate of 24.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 14.7% per year.

Key information

24.3%

Earnings growth rate

36.1%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate14.7%
Return on equity-30.4%
Net Margin-31.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?

Dec 12
Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

Oct 04
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

May 12
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Mar 04
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Jan 18
Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Oct 04
The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Oct 03
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Oct 20
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?

Dec 17
Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?

Revenue & Expenses Breakdown

How CStone Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2616 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24457-142271407
31 Mar 24460-255326468
31 Dec 23464-367382528
30 Sep 23472-559449531
30 Jun 23481-750516534
31 Mar 23481-827546574
31 Dec 22481-903576614
30 Sep 22454-1,205616836
30 Jun 22426-1,5086551,059
31 Mar 22335-1,7146581,182
31 Dec 21244-1,9206611,305
30 Sep 21681-1,6226221,339
30 Jun 211,118-1,3245831,373
31 Mar 211,079-1,2725341,389
31 Dec 201,039-1,2214851,405
30 Sep 20519-1,4824241,480
30 Jun 20-2-1,7443631,556
31 Mar 20-1-1,9063521,476
31 Dec 190-2,0693411,396
30 Sep 1911-1,6883271,040
30 Jun 1912-1,246322725
31 Mar 1912-858256788
31 Dec 1813-470191850
30 Sep 1813-336130747
31 Dec 1710-10739213

Quality Earnings: 2616 is currently unprofitable.

Growing Profit Margin: 2616 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2616 is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.

Accelerating Growth: Unable to compare 2616's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2616 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.4%).

Return on Equity

High ROE: 2616 has a negative Return on Equity (-30.43%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 08:51
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CStone Pharmaceuticals is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Ling WangJ.P. Morgan
Sean WuMorgan Stanley